Source:http://linkedlifedata.com/resource/pubmed/id/18729190
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2008-9-22
|
| pubmed:abstractText |
NY-ESO-1 antigen is a prototype of a class of cancer/testis antigens. We carried out a clinical trial using NY-ESO-1 whole protein as a cancer vaccine for 13 advanced cancer patients. We have recently reported that vaccine elicited humoral and cellular immune responses in 9 cancer patients including 4 esophageal cancer patients, and clinical responses were also observed in 4 of 5 evaluable patients. In this study, we analyzed the responses in 8 esophageal cancer patients including 4 newly enrolled patients. Patients were injected subcutaneously at biweekly intervals with NY-ESO-1 recombinant protein formulated with cholesterol-bearing hydrophobized pullulan. Induction of antibody, and CD4 and CD8 T-cell responses were observed in 7, 7 and 6 patients, respectively, out of 8 patients. 1 PR, 2 SD and 2 mixed clinical responses were observed in 6 evaluable patients. No significant adverse events were observed. Furthermore, we analyzed NY-ESO-1 and MHC class I expression and the infiltration of immune cells into tumor samples obtained before and after vaccination from 4 patients by immunohistochemistry. The results showed 2 patients with disappearance of CD4 and CD8 T-cell infiltration, 1 patient with increase in the number of CD68(+) macrophages and 1 patient with tumor antigen loss in the progressive tumors following vaccinations. The induction of NY-ESO-1 immunity and some preferable clinical outcomes were observed in esophageal cancer patients by vaccination with NY-ESO-1. However, the tumors grew eventually by various mechanisms after vaccination.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1097-0215
|
| pubmed:author |
pubmed-author:DokiYuichiroY,
pubmed-author:HoffmanEric WEW,
pubmed-author:IsobeMidoriM,
pubmed-author:IwaeShigemichiS,
pubmed-author:JungbluthAchim AAA,
pubmed-author:KawabataRyoheiR,
pubmed-author:MiyataHiroshiH,
pubmed-author:MondenMoritoM,
pubmed-author:MurphyRogerR,
pubmed-author:NakamuraYurikaY,
pubmed-author:NakayamaEiichiE,
pubmed-author:OldLloyd JLJ,
pubmed-author:RitterGerdG,
pubmed-author:SatoEiichiE,
pubmed-author:ShikuHiroshiH,
pubmed-author:UenakaAkikoA,
pubmed-author:WadaHisashiH,
pubmed-author:YamasakiMakotoM,
pubmed-author:YonezawaKouichiroK
|
| pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
123
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2362-9
|
| pubmed:meshHeading |
pubmed-meshheading:18729190-Aged,
pubmed-meshheading:18729190-Antigens, Neoplasm,
pubmed-meshheading:18729190-Cancer Vaccines,
pubmed-meshheading:18729190-Esophageal Neoplasms,
pubmed-meshheading:18729190-Female,
pubmed-meshheading:18729190-Humans,
pubmed-meshheading:18729190-Immunity, Cellular,
pubmed-meshheading:18729190-Immunohistochemistry,
pubmed-meshheading:18729190-Male,
pubmed-meshheading:18729190-Membrane Proteins,
pubmed-meshheading:18729190-Middle Aged
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
|
| pubmed:affiliation |
Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. hwada@gesurg.med.osaka-u.ac.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|